Avenue Therapeutics, Inc.
ATXI
$0.252
$0.00190.76%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 11.01% | -25.97% | -11.20% | -14.49% | -21.83% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -22.40% | -27.72% | -28.20% | 1.79% | 80.77% |
| Operating Income | 22.40% | 27.72% | 28.20% | -1.79% | -80.77% |
| Income Before Tax | -11.52% | 10.03% | 49.64% | 13.29% | -191.09% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -11.52% | 10.03% | 49.64% | 13.29% | -191.09% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -60.36% | -62.59% | -57.14% | -53.85% | 117.65% |
| Net Income | -12.29% | 9.33% | 49.56% | 12.71% | -192.15% |
| EBIT | 22.40% | 27.72% | 28.20% | -1.79% | -80.77% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 85.04% | 82.93% | 91.07% | 70.01% | 36.20% |
| Normalized Basic EPS | 90.30% | 92.22% | 98.26% | 74.86% | 36.38% |
| EPS Diluted | 85.04% | 82.94% | 91.08% | 70.03% | 36.22% |
| Normalized Diluted EPS | 90.30% | 92.22% | 98.26% | 74.86% | 36.38% |
| Average Basic Shares Outstanding | 816.63% | 932.43% | 707.34% | 511.50% | 384.64% |
| Average Diluted Shares Outstanding | 816.63% | 932.43% | 707.34% | 511.50% | 384.64% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |